Wire · opportunities
IntraBio Announces U.S. FDA Approval of AQNEURSA® (levacetylleucine) for Ataxia-Telangiectasia
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The U.S. FDA approved AQNEURSA® (levacetylleucine) for treating ataxia in patients with ataxia-telangiectasia (A-T), making it the first and only approved treatment for this rare neurodegenerative disorder worldwide. The approval follows positive Phase 3 trial results demonstrating significant symptom improvement, with AQNEURSA already being commercially available.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You can now enter the rare disease treatment market for ataxia-telangiectasia with a proven drug approved by the FDA in the US. Expect rising patient demand and fewer competitive obstacles given this is the first drug approved globally for this indication.
◆ Coverage
4 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics